Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma |
| |
| Authors: | Premal H. Patel G. Varuni Kondagunta Lawrence Schwartz Nicole Ishill Jennifer Bacik John DeLuca Paul Russo Robert J. Motzer |
| |
| Affiliation: | (1) Genitourinary Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA;(2) Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA;(3) Department of Biostatistics, Epidemiology and Statistics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA;(4) Department of Surgery, Urologic Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA;(5) Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA |
| |
| Abstract: | Summary Lenalidomide (CC-5013) is a structural derivative of thalidomide, with antiangiogenic and immunomodulatory effects. Fourteen patients with metastatic renal cell carcinoma (RCC) were enrolled on a phase 2 trial of lenalidomide administered orally at 25 mg daily for 21 days followed by a rest period of 7 days. The best response was stable disease in eight patients (57%) of the 14 evaluable patients. Toxicities included fatigue, hyperglycemia, dyspnea, and myelosuppression with decreased hemoglobin, lymphopenia, and neutropenia. Lenalidomide is tolerable, but no objective responses were observed in this clinical trial. |
| |
| Keywords: | Renal cell carcinoma Lenalidomide Thalidomide CC-5013 Phase II |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
